Table 1.
Total (n = 2786) | Primary prevention (n = 1718) | Secondary prevention (n = 1068) | |
---|---|---|---|
Clinical characteristics | |||
Age (years) | 61 ± 13 | 62 ± 13 | 61 ± 14 |
Male (%) | 2192 (79) | 1336 (78) | 856 (80) |
Left ventricular ejection fraction (%) | 33 ± 15 | 31 ± 14 | 39 ± 16 |
QRS, mean (SD), ms | 125 ± 34 | 129 ± 35 | 119 ± 32 |
Renal clearance, mean (SD), mL/min | 81 ± 37 | 81 ± 36 | 82 ± 39 |
Ischaemic heart disease (%) | 1800 (65) | 1077 (63) | 723 (68) |
History of atrial fibrillation/flutter (%) | 683 (25) | 447 (26) | 236 (22) |
Medication | |||
ACE-inhibitors/AT II antagonist (%) | 2107 (76) | 1407 (82) | 700 (66) |
Aspirin (%) | 1107 (40) | 649 (38) | 458 (43) |
Beta-blocker (%) | 1513 (54) | 1074 (63) | 439 (41) |
Diuretics (%) | 1738 (62) | 1221 (71) | 517 (48) |
Statins (%) | 1610 (58) | 1075 (63) | 535 (50) |
Anti-arrhythmic medicationa | |||
Amiodarone (%) | 497 (18) | 221 (13) | 276 (26) |
Sotalol (%) | 386 (14) | 184 (11) | 202 (19) |
ACE, angiotensin-converting enzyme; AT, angiotensin; SD, standard deviation.
aPatients could be taking >1 anti-arrhythmic drug.